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ABSTRACT
Introduction International policy imperatives for the 
public and patient involvement in the governance 
of health data coexist with conflicting cross- border 
policies on data sharing. This can challenge the planning 
and implementation of participatory data governance 
in healthcare services locally. Engaging with local 
stakeholders and understanding how their needs, 
values and preferences for governing health data can be 
articulated with policies made at the supranational level is 
crucial. This paper describes a protocol for a project that 
aims to coproduce a people- centred model for involving 
patients and the public in decision- making processes 
about the use and sharing of health data for rare diseases 
care and research.
Methods and analysis This multidisciplinary project 
draws on an explanatory sequential mixed- methods study. 
A hospital- based survey with patients, informal carers, 
health professionals and technical staff recruited at two 
reference centres for rare diseases in Portugal will be 
conducted first. The qualitative study will follow consisting 
of semi- structured interviews and scenario- based 
workshops with a subsample of the participant groups 
recruited at baseline. Quantitative data will be analysed 
using descriptive and inferential statistics. Inductive 
and deductive approaches will be combined to analyse 
the qualitative interviews. Data from scenario- based 
workshops will be iteratively compared using the constant 
comparison method to identify cross- cutting themes and 
categories.
Ethics and dissemination The Ethics Committee for 
Health from the University Hospital Centre São João/
Faculty of Medicine of University of Porto approved the 
study protocol (Ref. 99/19). Research findings will be 
disseminated at academic conferences and science 
promotion events, and through public meetings involving 
patient representatives, practitioners, policy- makers and 
students, a project website and peer- reviewed journal 
publications.
INTRODUCTION
How to govern health data has become a 
question of unprecedented relevance in 
the golden age of data sharing.1 Large- scale 
health data repositories aggregating multiple 
datasets hold enormous predictive and trans-
formation potential to improve population 
health and well- being.2 This is especially 
promising in the field of rare diseases, where 
transnational data sharing is likely to inten-
sify as a result of increased sponsorship by the 
European Commission (EC).3 Yet how health 
data are shared and used also carries risks and 
causes public concern.4 International policy 
agencies recommend public participation in 
Strengths and limitations of this study
 ► This study will contribute to help reducing health 
data policy implementation gaps by coproducing 
a model for public and patient involvement in data 
governance in the context of rare diseases.
 ► Another of its strengths is its people centred, multi-
disciplinary approach designed to elicit stakehold-
ers’ expertise to identify challenges to and devise 
strategies for enacting participatory health data 
governance.
 ► The project combines the strengths of quantitative 
and qualitative methods, maximising the latter’s 
potential to facilitate the engagement of patients 
and the public with the topic of health data use and 
sharing.
 ► Although project funds only allow for data collection 
at two reference centres for rare diseases at one 
academic hospital centre, this study site was pur-
posefully selected because it would enable access 
to stakeholders involved in national and internation-
al data sharing for research.
 ► Challenges associated with the study’s multi-
phase design include participant attrition between 
questionnaires, semistructured interviews and the 
scenario- based workshop, and lower response 
rates, namely by people who may be less resourced 
to participate or interested in research.
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data governance as a means to improve safeguards, reduce 
risks and increase the benefits arising from health data 
processing.5 6 But such recommendations exist alongside 
conflicting cross- border policies on data sharing7 8 that 
can thwart its implementation. Engaging with local stake-
holders and understanding how their needs, values and 
preferences can be articulated with policies made at the 
supranational level is therefore a pressing concern.
Processing of large sets of health data can help to 
prevent, diagnose and cure hundreds of diseases.9 10 It 
can also improve clinical practice and quality of care, 
reduce public health threats and advance health policy 
goals.6 9 11 12 However, information security and privacy 
have been challenged by data breaches and misman-
agement that can lead to participants’ unduly identifi-
cation.13 14 Unforeseen access to health data by private 
companies also raises concerns with confidentiality and 
inappropriate data use, including results commercialisa-
tion and undisclosed surveillance.4 15 16 These risks can 
erode public trust in the organisations that handle their 
data, reducing potential for innovation.4 17 To address 
these issues, several international legal instruments 
and recommendations have been produced.5 6 18 They 
emphasise the importance of involving the public in the 
development of a shared policy framework to govern the 
protection of privacy, data security and transnational data 
flows.5 6
Rare diseases offer a paradigmatic example of the 
opportunities and challenges involved in the governance 
of health data. Their rareness, diversity and complexity 
demand collaboration and sharing of patient data between 
experts internationally. Data- sharing partnerships are key 
to overcome difficulties of conducting research in this 
field: case numbers are low and there is insufficient avail-
ability of technological tools needed to conduct genetic 
testing and genome sequencing.19 20 Yet this type of 
collaboration is difficult as data on rare diseases is sparse, 
dispersed and unsystematically collected and stored.21 To 
tackle this problem, the EC has recently funded the Euro-
pean Reference Networks (ERN) to set up rare disease 
patient registries.3 ERNs are expected to develop interop-
erable registries and to build synergetic partnerships for 
knowledge and data exchange.22 Realising these goals will 
prompt the flow of large amounts of data and technolo-
gies between member states.
Cross- border health data sharing raises additional 
ethical, legal and social challenges. These include unau-
thorised data reuse and unwanted return of incidental 
findings from research,4 23 which compromise individ-
uals’ autonomy and entitlement to an open future (eg, 
anticipating the diagnosis of an untreatable adult- onset 
disorder through return of unsolicited genetic testing 
results).24 The EU General Data Protection Regulation, 
enforced since May 2018, aims to address some of these 
challenges, not least through the rights to be forgotten 
and to data portability.18 It does so on the footprints of two 
sets of policies on research and innovation. One of those 
policies promotes data sharing and harmonisation of 
international rules toward a paradigm of ‘open science’.25 
The other one is underlined by ethical concerns with 
autonomy and privacy protection and asserts the need 
to control data flows.26 These data- sharing policies host 
mutually incompatible rules that can give rise to tensions 
when implemented7 27: healthcare providers, for example, 
may struggle to combine the protection of patients’ right 
to privacy while seeking to abide by the principles of 
open- access.
Participatory health data governance
Increasing support for participatory health data gover-
nance, whereby patients and other members of the public 
are involved in consultations and decision making about 
health data, is premised on the idea that this process can 
increase accountability in data processing, reduce unnec-
essary harms and enhance the fair distribution of the bene-
fits of data use.5 6 8 28 Participatory data governance is also 
encouraged as a way of promoting dialogue about ethical, 
legal and social issues and imbuing research policy with 
socioethical sensitivity.29–32 Collaboration between lay and 
research experts can infuse research with social values and 
facilitate the codesign of innovative solutions for complex 
problems.20 31 However, those collaborative relationships 
are not always easy to develop.33 Careful attention is 
needed to create participatory spaces that are inclusive 
and harness everyone’s potential for contribution.34–36 
Competing interests, and an unbalanced distribution of 
the resources needed for meaningful participation, can 
cause disadvantaged groups to be excluded from deci-
sion making, which in turn risks to reproduce ethnic, 
age, gender and socioeconomic inequalities or to even 
generate new ones (eg, digital exclusion).34 37–40 There is 
thus an unequivocal need to assess the potential benefits 
and risks of public and patient involvement in health data 
governance and to develop a people- centred, bottom- up 
approach to participation that responds to local stake-
holders’ interests and needs. This project aims to reach 
this goal by collaborating with stakeholders engaged in 
care and research for rare diseases at an academic hospital 
centre in Portugal. Its specific aims are to:
1. Assess the needs and preferences of rare diseases pa-
tients, their informal carers, health professionals and 
technical staff concerning decision making about the 
use and sharing of health data for rare diseases care 
and research.
2. Understand those stakeholders’ expectations of and 
perspectives about public and patient involvement in 
health data decision- making processes, including their 
views on the ethical, legal and social implications of 
participation.
3. Coproduce a people- centred model for public and pa-
tient involvement in health data governance.
DATAGov is led by a multidisciplinary team working 
at the crossroads of sociology, public health and clinical 
medicine and with long- term experience in collaborating 
with rare diseases community organisations and networks. 
The project will contribute to advance international 
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policy imperatives for public and patient involvement in 
health data governance and to improve its practice. It will 
do so by creating opportunities for stakeholders to discuss 
the implementation of participatory data governance in a 
healthcare setting and by eliciting their collective exper-
tise to devise strategies to address emerging ethical, legal 
and social challenges.
METHODS AND ANALYSIS
Study design and setting
This project adopts an explanatory sequential mixed- 
methods design, collecting and analysing quantitative 
and qualitative data.41 The quantitative phase is first in 
the sequence and draws on a hospital- based survey with 
rare disease patients, informal carers, health profes-
sionals and technical staff recruited at the University 
Hospital Centre São João (UHCSJ), in Porto, Portugal. 
The qualitative phase relies on semistructured interviews 
and scenario- based workshops with a subsample of the 
participants recruited at baseline. Survey and interview 
data will be collected to examine stakeholders’ needs, 
preferences, expectations and perspectives of public 
and patient involvement in health data decision making. 
These findings will be subsequently integrated to develop 
a set of scenarios for participatory health data governance, 
which will be presented at the scenario- based workshops. 
Representatives of all stakeholder groups will be invited 
to discuss the scenarios and to select a preferred model 
for involving patients and other members of the public 
in the governance of health data (see table 1). Integra-
tion of quantitative and qualitative findings will provide 
an understanding of the ethical, legal and social implica-
tions of participatory data governance.
Data will be collected in two reference centres for 
rare diseases at the UHCSJ. These research settings were 
purposefully sampled because: (1) they were among the 
first reference centres to be created in Portugal in 2016 
and are acknowledged for their expertise and clinical 
practice; (2) they are in charge of overseeing patients 
from the entire Northern Health Region of Portugal, 
which allows for larger study samples; (3) one is affiliated 
with an ERN and the other is awaiting a final decision on 
its application for membership and (4) they are involved 
in national and international research projects, which 
presents an excellent case to explore first- hand experi-
ences of decision making regarding patient data use and 
sharing.
Study procedures and analysis
Hospital-based survey
Rare diseases patients, informal carers, health profes-
sionals and technical staff will be invited to participate in 
a survey conducted at the UHCSJ to assess their prefer-
ences and needs regarding decision making concerned 
with health data use and sharing.
During a 6- month period, patients aged 12 and above 
who attend a consultation in the reference centres at 
the UHCSJ, who can read and write in the Portuguese 
language and without cognitive impairment will be consec-
utively recruited to participate in the study, together with 
their informal carers. Medicine and nursing unit staff of 
the reference centres outpatient clinics will distribute 
study information leaflets to potential participants, or 
their guardians, after patients’ biometric screening 
appointments or medical consultations. Two researchers 
will be at the hospital site to provide additional informa-
tion and to invite patients and informal carers to inde-
pendently fill in a self- report structured questionnaire, 
after obtaining informed consent. Underage participants 
will be invited to complete the questionnaire individually, 
after giving verbal consent and their carers signing the 
written consent form. Adult survey participants will be 
asked for consent to be contacted and invited to a semi- 
structured interview approximately 4 months later.
Directors and managers of relevant units and depart-
ments at the UHCSJ will be provided with recruitment 
emails, along with study information sheets, to invite 
health professionals from the reference centres’ multi-
disciplinary teams (ie, doctors, nurses and allied health 
Table 1 Mixed- methods research objectives, procedures and analysis
Objective Study procedure Sampling and participants Data analysis
To assess stakeholders’ needs 
and preferences concerning 
decision- making about health 
data use and sharing
Hospital- based survey Consecutive sampling at two reference centres 
for rare diseases of an estimated 200 patients, 
500 informal carers, 70 health professionals and 
30 technical staff
Descriptive and regression 
analysis, adjusting for 
confounders
To understand stakeholders’ 
expectations and perspectives 
about public and patient 
involvement in health data 
decision- making processes
Qualitative interviews Subsample of quantitative study selected through 
heterogeneity sampling including an estimated 
30 patients, 30 informal carers, 15 health 
professionals and 10 technical staff
Inductive and deductive analysis 
informed by the Modified 
Participation Chain Model
To coproduce a model for 
public and patient involvement 
in health data governance
Scenario- based 
workshops
Subsample of quantitative study selected 
through heterogeneity sampling including 
8–12 participants per stakeholder group in the 
intragroup round and three participants per 
stakeholder group in the mixed- group round (total 
of 12 participants)
Deductive and inductive 
approach to scenario 
development followed by 
inductive analysis of workshops 
data
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professionals) and technical staff to partake in the survey. 
Questionnaires will be delivered to potential participants 
after obtaining informed consent by two researchers over 
a 2- month period.
Questionnaire development was informed by current 
literature and a review of existing questionnaires related 
to the research topic. Professional experts from the 
health and social sciences (eg, general practitioner, 
psychologist, specialist doctor, researcher) were asked to 
pretest the structured questionnaire, which was revised 
and subsequently piloted with a group of patients (n=5) 
and informal carers (n=22). This resulted in modifi-
cations to wording and in some items being removed. 
The final questionnaire for patients and informal carers 
includes 38 questions covering four major topics: (1) 
positioning regarding data use and sharing for care and 
research purposes; (2) preferences and needs regarding 
data use and sharing; (3) opinions about public and 
patient involvement in health data governance and 
(4) sociodemographic characteristics. The question-
naire was adapted to accommodate professionals and 
technical staff, resulting in a slightly shorter version for 
these groups. A translation of the full questionnaire by 
the authors is available as online supplemental material. 
Questionnaires require an average of 15 min to fill in. We 
expect participation by 200 patients, 500 informal carers 
and 70 health professionals and 30 technical staff.
Statistical analyses will be performed using IBM SPSS 
V.25.0. Data will be described as counts and proportions 
for categorical variables, mean and SD for normally 
distributed continuous variables, and median and IQR for 
non- normally distributed continuous variables. Different 
analytic approaches will be performed to tackle the 
specific objectives established. Means will be compared 
with the Student’s t- test or Mann- Whitney test, as appro-
priate, and differences in frequencies and proportions of 
categorical variables will be assessed using the χ2 test or 
the Fisher’s exact test. The OR and respective 95% CI will 
be calculated by logistic regression models to estimate the 
associations between explanatory variables (eg, sex, age, 
educational level, working status, occupation, perceived 
income adequacy, involvement with patient associa-
tions, satisfaction with own health, social trust) and the 
outcomes, which will include willingness to share health 
data for care and research purposes, importance given 
to participation in decision making about data use and 
sharing, preferred forms of consent to data use and will-
ingness for and preferred modes of public and patient 
involvement in health data governance in a healthcare 
setting.
Qualitative interviews
To deepen our understanding of stakeholders’ expecta-
tions and perspectives of public and patient involvement 
in health data decision making, semistructured interviews 
will be conducted with a subsample of the adult partici-
pants who completed the questionnaire. Approximately 
4 months after participation in the survey, patients and 
informal carers who consented to being contacted will be 
invited by telephone or email to take part in an individual 
qualitative interview. Health professionals and technical 
staff will be invited to participate through email. Hetero-
geneity sampling will be employed to obtain maximum 
variation in perspectives and experiences and allow theo-
retical saturation to be reached.42 43 Interviews will be 
held at a time and place of participants’ preference (eg, 
university department, work place, home). Participant 
information sheets and consent forms will be provided 
alongside with a request to audiorecord the interviews.
Questions for the interview guide are exploratory and 
informed by existing literature. They address four main 
topics: (1) personal experience with involvement in 
patient organisations and/or illness; (2) facilitators of and 
barriers to health data sharing; (3) views about individual 
participation in decision- making concerning health data 
use and sharing and, (4) perspectives about public and 
patient involvement in health data governance. Interviews 
are expected to last between 30 min and 1 hour. We esti-
mate to conduct interviews with 30 patients, 30 informal 
carers, 15 health professionals and 10 technical staff.
Data analysis will proceed hand in hand with data collec-
tion for timely identification of informational redun-
dancy and subsequent discontinuation of sampling.42 44 
Interview transcripts will be analysed iteratively by two 
researchers with the support of NVivo V.12. Inductive 
analysis will be performed first using open, selective and 
axial coding to facilitate the emergence of categories 
and core themes.43 Deductive analysis will follow drawing 
on relevant theoretical frameworks, namely the Modi-
fied Participation Chain Model (MPCM).34 The MPCM 
asserts that public involvement in health decision making 
is influenced by a set of mutually constitutive factors that 
evolve through participation when the right institutional 
dynamics are in place. These factors include individual 
and collective motivations, mobilisation efforts, resources 
and the dynamics of participation. They influence not 
only people’s willingness to get involved but also their 
capacity and resolve to participate. These acumens will 
be used to load inductive themes with theoretical sensi-
tivity.43 Triangulation of interview data sources and of 
data analysts will be employed to ensure the rigour and 
quality of the findings.45
Stakeholders’ views will provide in depth insight in:
 ► How they may be driven to or detracted from data use 
and sharing for care and research and whether that is 
explained by perceived benefits and risks?
 ► Their stand concerning the involvement of different 
publics in collective decision- making about health 
data.
 ► Their views about the ethical, legal and social impli-
cations of participatory health data governance and 
proposed solutions to overcome potential challenges.
Scenario-based workshops
Scenario- based workshops46 will be held to coproduce a 
people- centred model for public and patient involvement 
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in health data governance. This foresight method was 
chosen for its potential to facilitate the engagement of 
patients and the public in the development of health 
policy at local and national levels46–49 and it will be used 
to incorporate participants’ collective expertise into a 
model for participatory data governance.
Survey and interview data will be integrated and 
combined with extant literature to inform the design 
of a set of scenarios for involving different stakeholders 
in collective decision- making processes concerned with 
health data. The scenarios will be presented in workshops 
with representatives from rare diseases patients, informal 
carers, health professionals and technical staff to enable 
critical dialogue. The scenario- based workshops will be 
carried out in two rounds: (1) round 1 will entail four 
intra- group workshops conducted with each stakeholder 
group separately (8–12 participants). Participants will be 
asked to evaluate the relevance and feasibility of each 
scenario and to assess its potential ethical, legal and social 
implications; (2) round 2 will entail two mixed- group 
workshops including a similar number of representa-
tives from each stakeholder group (n=3) in a total of 12 
participants. Stakeholders’ feedback from round 1 will be 
used to make revisions to the first set of scenarios. The 
revised scenarios will be offered for discussion in round 
2, in which participants will be asked to select a preferred 
model for public and patient involvement in health data 
governance.
Round 1 participants will be selected per stakeholder 
group and from the baseline sample through heteroge-
neity sampling, stratified by gender and educational level. 
They will be invited to participate by email or telephone, 
following their expressed preferences. A subsample of 
round 1 participants will be randomly selected to take part 
in round 2. The scenario- based workshops will be held 
in the venues considered most accessible by participants 
(eg, university department). They will be moderated by 
an experienced researcher supported by two observers 
who will carry out observation and note- taking. They are 
expected to last approximately 2 hours. Permission to 
audiorecord the workshops will be requested. Recordings 
will be transcribed verbatim and used for interpretational 
analysis with the assistance of NVivo V.12. Following open, 
axial and selective coding,43 data from each scenario- 
based workshop will be iteratively compared with data 
from other, same- round scenario- based workshops using 
the constant- comparison method50 to identify cross- 
cutting core themes and categories.
The scenario- based workshops will offer insights about:
 ► What motivates stakeholders to get involved in collec-
tive decision making about health data?
 ► Which resources are needed to promote meaningful 
participation by all stakeholders involved?
 ► How stakeholders can be best informed about and 
mobilised to undertake opportunities for involvement 
in health data governance?
 ► How collaborative participation dynamics may be 
achieved so as to accommodate stakeholders’ needs, 
values and preferences and inform a people- centred 
model for participatory data governance?
Public and patient involvement
The project’s research question was informed by a 
previous empirical study conducted by some of the authors 
in which rare diseases community experts expressed 
the need to play an active role in decisions about how 
their health data is used.20 Representatives of patients, 
informal carers, health professionals and researchers 
were involved in questionnaire and interview guide vali-
dation through pretesting and piloting. Their feedback 
was used to adapt its contents and to keep their length 
to a feasible minimum. In addition, the following strate-
gies will be used to promote inclusivity in study participa-
tion: participants will be recruited by health professionals 
in a consecutive way, after their medical appointments; 
research team members will support participants during 
questionnaire completion, clarifying any arising doubts 
and interviews and scenario- based workshops will accom-
modate participants’ scheduling and place preferences 
(eg, weekends; close to work).
The project’s ultimate aim is to facilitate the co- pro-
duction of a model for participatory health data gover-
nance. This will be achieved through involvement of 
a variety of stakeholders in critical dialogue about how 
to govern health data using scenario- based workshops. 
Participatory exercises that engage stakeholders with 
different backgrounds and interests offer an opportunity 
to expand knowledge and effect change that matters to 
increasingly diverse constituencies.34 However, they may 
also cause the powerful- powerless gap to become more 
salient if the voices of groups traditionally lacking in equi-
table social participation are silenced.38 51 To prevent the 
latter, patients and informal carers will be provided with 
a training in preparation for the scenario- based work-
shops. All participants will be informed of the purposes 
and dynamics (eg, moderators’ and participants’ roles; 
appropriate rules of conduct) of the scenario- based 
workshops prior to their start. Furthermore, intragroup 
scenario- based workshops will be held first, to ensure 
that the perspectives of all stakeholder groups are elic-
ited and incorporated in the scenarios presented at the 
mixed- group workshops. All workshops will be facilitated 
by academic leads with experience in involving patients 
and the public in healthcare research.20
Stakeholder representatives will also be involved in 
research findings dissemination through participation 
in public meetings and science promotion events. The 
project website will provide a contact platform that stake-
holders and the general public can use to address ques-
tions and comments to the research team.
ETHICS AND DISSEMINATION
The study protocol received ethical approval from the Ethics 
Committee for Health from the UHCSJ/Faculty of Medicine 
of University of Porto (Ref. 99/19).
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To ensure data confidentiality and protection, participants’ 
identifying information will only be available to four research 
team members, who will sign a non- disclosure agreement. 
Other researchers will be provided pseudoanonymised 
data.52 Questionnaires, interviews and scenario- based work-
shops will be conducted in a private place after obtaining 
consent. Personal contacts, consent forms, questionnaires, 
audiorecordings and transcripts will be coded and kept sepa-
rately in computer files protected by password and in locked 
cabinets. Audio and transcribed data will be securely stored 
for a period of 5 years and eliminated afterwards.
Survey and interview research findings will be reported first 
to stakeholders at the in- group scenario- based workshops to 
identify areas of convergence and tension and prepare for 
inter- group dialogue about participatory data governance. In 
addition, the findings will be disseminated to a broad audi-
ence through peer- reviewed journal publications, academic 
conferences, a project website and science promotion events 
involving patient representatives, practitioners, policy- makers 
and students.
The project was initially planned to last 36 months, starting 
in July 2018. However, an extension of 12 months was 
requested to compensate for fieldwork constraints caused 
by the COVID-19 pandemic. The project is thus expected to 
run from July 2018 to July 2022. Adjustments to data collec-
tion and dissemination, including the use of online tools 
(eg, online questionnaires, webinars), will be made if the 
measures undertaken locally to address the pandemic so 
require.
EXPECTED OUTCOMES AND RELEVANCE
International policy recommendations for public involve-
ment in data governance6 exist amidst conflicting data- 
sharing policies.7 27 This can challenge the effective planning 
and implementation of participatory data governance in 
local healthcare services. DATAGov is set to coproduce a 
people- centred model for collective participation in decision- 
making about data use and sharing for rare diseases care and 
research. To that end, it will help build collective expertise 
by a wide range of stakeholders, including patients and lay 
members of the public, both to unravel the social, legal and 
ethical implications of participatory data governance and to 
devise bottom- up strategies to address emerging problems.
Project results will contribute to inform and improve the 
practice of public and patient involvement in health data 
governance, nationally and internationally, by expanding 
the evidence base on stakeholders’ stands, concerns and 
preferred roles regarding data decision- making processes. 
Undeniably, DATAGov is a timely and much needed 
response to calls for moving away from ‘hypothetical person- 
centred approaches that presume a universal ‘reasonable 
person’ standard’ into empirically grounded accounts of data 
governance8 that acknowledge the heterogeneity of interests 
underlining the constitution of different publics.40 53 As such, 
it will help to reduce policy implementation gaps by facili-
tating the coproduction of a data governance model more 
attuned with citizens’ expectations, needs and preferences.
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